Oncotarget

Research Perspectives:

When does a melanoma metastasize? Implications for management

John F. Thompson _ and Gabrielle J. Williams

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2024; 15:374-378. https://doi.org/10.18632/oncotarget.28591

Metrics: PDF 475 views  |   Full Text 1161 views  |   ?  


Abstract

John F. Thompson1,2,3,4 and Gabrielle J. Williams1,2

1 Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia

2 Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

3 Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia

4 Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, Australia

Correspondence to:

John F. Thompson, email: [email protected]

Keywords: melanoma; metastasis; time; adjuvant systemic therapy; tumor doubling time

Received: May 23, 2024     Accepted: May 29, 2024     Published: June 13, 2024

Copyright: © 2024 Thompson and Williams. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Selecting which patients with clinically-localized melanoma require treatment other than wide excision of the primary tumor is based on the risk or presence of metastatic disease. This in turn is linked to survival. Knowing if and when a melanoma is likely to metastasize is therefore of great importance. Several studies employing a range of different methodologies have suggested that many melanomas metastasize long before the primary lesion is diagnosed. Therefore, waiting for dissemination of metastatic disease to become evident before making systemic therapy available to these patients may be less effective than giving them post-operative adjuvant therapy initially if the metastatic risk is high. The identification of these high-risk patients will assist in selecting those to whom adjuvant systemic therapy can most appropriately be offered. Further studies are required to better identify high-risk patients whose primary melanoma is likely to have already metastasized.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28591